No Data
No Data
Is Incyte Stock Underperforming the Nasdaq?
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Incyte Corporation's (NASDAQ:INCY) Business And Shares Still Trailing The Industry
Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET